We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 19 oktober 2018

Nature Reviews Clinical Oncology - Table of Contents alert Volume 15 Issue 11

Nature Reviews Clinical Oncology


Advertisement
The Independent and Unbiased Molecular Information Company 

Tumor profiling with Caris Molecular Intelligence® assesses DNA, RNA and proteins to reveal a molecular blueprint in order to guide more precise and personalized treatment decisions. We are committed to ensuring that the right drug gets to the right patient at the right time, without drug recommendation bias.

Your trusted intermediary in molecular profiling

Learn more >
TABLE OF CONTENTS

November 2018 Volume 15, Issue 11

Editorial
Research Highlights
News & Views
Reviews

Advertisement
===================================
Register for the latest nature.com webcast


Assembling High-quality Genomes to Solve Nature's Mysteries - Thursday, November 1, 2018 

Register for FREE today

Sponsored by Pac Bio

==================================


Advertisement
Nature Outlook: Brain cancer 

The uncontrolled growth of a tumour inside the brain creates an extraordinarily potent threat to our being. A diagnosis of brain cancer still carries the high likelihood of death within five years. But efforts to prolong survival are advancing on several fronts. 

Access free online

Produced with support from 

Novocure 
 

Editorial

The murky world of disclosures   
Peter Sidaway
p651 | doi:10.1038/s41571-018-0106-z
Full Text | PDF



Research Highlights

Insights into the risk of fatal AEs with ICIs
David Killock
p653 | doi:10.1038/s41571-018-0104-1
PDF



Immunogenomic features of mCRPC revealed
Peter Sidaway
p654 | doi:10.1038/s41571-018-0098-8
PDF



Erlotinib effective in the neoadjuvant setting
Peter Sidaway
p654 | doi:10.1038/s41571-018-0099-7
PDF



PD-1 mRNA predicts response to therapy
Peter Sidaway
p654 | doi:10.1038/s41571-018-0100-5
PDF



Signatures IMPRES and might turn the TIDE in predicting responses
David Killock
p654 | doi:10.1038/s41571-018-0088-x
PDF



ctDNA predicts outcomes in DLBCL
Peter Sidaway
p655 | doi:10.1038/s41571-018-0091-2
PDF
Collection: Haematological cancer



Mesothelioma risk genes revealed
Peter Sidaway
p655 | doi:10.1038/s41571-018-0092-1
PDF



EMBRACing a new PARP inhibitor?
Diana Romero
p655 | doi:10.1038/s41571-018-0090-3
PDF



Nature Reviews Clinical Oncology
EVENT
4th Oncolytic Virotherapy Summit
04.12.18
Boston, USA
More science events from
Advertisement
Do you have a career question?

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!
 

News & Views

Viruses in cancer therapy — from benchwarmers to quarterbacks
Pierpaolo Peruzzi & E. Antonio Chiocca
pp657 - 658 | doi:10.1038/s41571-018-0077-0
PDF



Infant medulloblastoma — learning new lessons from old strata
Marc Remke & Vijay Ramaswamy
pp659 - 660 | doi:10.1038/s41571-018-0071-6
PDF



Precision risk-based screening might maximize benefit and minimize harm
Laura J. Esserman & Andrea Z. LaCroix
pp661 - 662 | doi:10.1038/s41571-018-0093-0
PDF



Reviews

Alternative splicing in prostate cancer   
Alec Paschalis, Adam Sharp, Jonathan C. Welti, Antje Neeb, Ganesh V. Raj et al.
pp663 - 675 | doi:10.1038/s41571-018-0085-0
Androgen receptor (AR) splice variants (AR-Vs) are truncated isoforms of the AR, of which a subset remain constitutively active in the absence of circulating androgens. AR-Vs have been proposed to contribute to therapeutic resistance. The authors of this Review outline the current understanding of the role of the spliceosome in prostate cancer progression and explore the therapeutic utility of manipulating alternative splicing.
Full Text | PDF



Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy   
Elizabeth Ahern, Mark J. Smyth, William C. Dougall & Michele W. L. Teng
pp676 - 693 | doi:10.1038/s41571-018-0095-y
Intriguing evidence suggests that expression of RANK or RANKL by various cells of the tumour microenvironment modulates the anticancer immune response. Herein, the authors review this evidence, discuss the current preclinical and clinical data supporting a potential of RANKL inhibition to improve anticancer immunotherapy and describe hypothetical immune-related mechanisms of action.
Full Text | PDF



Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?   
Gonzalo Recondo, Francesco Facchinetti et al.
pp694 - 708 | doi:10.1038/s41571-018-0081-4
The clinical management of patients with non-small-cell lung carcinoma has greatly evolved owing to the development of tyrosine-kinase inhibitors (TKIs) targeted against the driver mutations of this disease. The authors of this Review describe the existing evidence on the sequential administration of TKIs and the use of next-generation TKIs upfront.
Full Text | PDF



Therapeutic strategies to target RAS-mutant cancers   
Meagan B. Ryan & Ryan B. Corcoran
pp709 - 720 | doi:10.1038/s41571-018-0105-0
Effective therapeutic strategies to target RAS-mutant cancers have proved elusive, but in the past few years, several promising strategies have been tested in clinical trials. The authors describe historical and ongoing therapeutic approaches based on the direct or indirect targeting of RAS.
Full Text | PDF



Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

This email has been sent to dezorgsector.uk@gmail.com.

If you no longer wish to receive the email alerts from Nature Reviews Clinical Oncology click here to unsubscribe .
If you wish to discontinue all email services from Nature Research please click here to unsubscribe .

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature